Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
10.80
-0.36 (-3.23%)
Jun 5, 2025, 10:24 AM - Market open
Bicara Therapeutics Employees
Bicara Therapeutics had 55 employees as of December 31, 2024.
Employees
55
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,678,782
Market Cap
588.99M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 55 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
BCAX News
- 1 day ago - Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire
- 3 days ago - Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 - GlobeNewsWire
- 12 days ago - Bicara: Stock Decline On FICERA Abstract Release Creates Buying Opportunity - Seeking Alpha
- 13 days ago - Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 23 days ago - Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025 - GlobeNewsWire
- 6 weeks ago - Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 6 weeks ago - Bicara: Innovative Precision Tumor Targeting - Seeking Alpha